Second, there is no consideration of tumor location; this is because the efficacy of anti-EGFR monoclonal antibody in right-sided colon cancer was first reported in ASCO 2016 while the protocol of the present study was waiting approval from the ethics committee. Here, EGFR is linked to neoplasm.